
NYSE:CVS
Likes diversified health care like this, including health insurance and pharmacy. They bought Oak Street for $9.5 billion and 10% of their market cap. Not profitable yet, but CVS will integrate Oak Street and raise profits. They just hired from Humana for Aetna a new and smart president. Sells at a good valuation and pays a 3.5% dividend. Weakness partially comes from not passing on higher costs to customers. He's held CVS for a while and has gone round-trip.
(Analysts’ price target is $107.13)
They do drug retail in the U.S. Also have a PBM business and health insurance. Their strategy is to broaden their offerings by buying companies. She owned this a few years ago. Trades at a low PE, but all those purchases and PBM is limited by outside forces to limit health costs, so this is an overhang.
Inexpensive. Frontline pharmacy, insurance, and PBM all rolled into one. Just bought a healthcare provider to tap into in-home and rural opportunities. Less than 10x earnings, big free cashflow. Market's nervous about debt, about $20B. CEO is a smart operator. Yield is 3.23%.
(Analysts’ price target is $112.27)
Acquisitions have hampered stock price. Targets keep getting pushed our further. Lowered guidance. May be support levels around this price. Trades at 8x forward earnings, well below its historical 12.5x PE. Growth remains elusive. Dividend's great at 3.5%.